Sifting through countless of stocks in the Life Sciences Tools & Services industry can be tedious, and sometimes two stocks are just too similar to judge which is the better investment. If you’re on the fence about investing in Bio-Rad Laboratories, Inc. or Qiagen N.V. because you’re not sure how they measure up, it’s important to compare them on a few factors before making your decision.

Read on to learn how Bio-Rad Laboratories, Inc. and Qiagen N.V. compare based on key financial metrics to determine which better meets your investment needs.

About Bio-Rad Laboratories, Inc. and Qiagen N.V.

Bio-Rad Laboratories, Inc. develops, manufactures, and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, Latin America, and internationally. It operates through two segments, Life Science and Clinical Diagnostics. The Life Science segment develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantify biological materials, including cells, proteins, and nucleic acids used in research and biopharmaceutical laboratory environments, as well as for biopharmaceutical manufacturing, quality control process, food safety, and science education applications. This segment serves universities and medical schools, industrial research organizations, government agencies, pharmaceutical manufacturers, biotechnology companies, food producers, and testing laboratories. Its Clinical Diagnostics segment designs, manufactures, markets, and supports diagnostic test systems, informatics systems, test kits, and specialized quality controls for clinical, hospital, diagnostic reference, and transfusion and physician office laboratories, as well as software. The company offers its products through its direct commercial organization, as well as through distributors, agents, brokers, and resellers. Bio-Rad Laboratories, Inc. was founded in 1952 and is headquartered in Hercules, California.

Qiagen N.V. provides sample to insight solutions that transform biological samples into molecular insights in the Netherlands and internationally. The company offers primary sample technology consumables, such as nucleic acid stabilization and purification kits for sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, such as kits and components for purification of nucleic acids; and instruments for nucleic acid purification, quality control, and accessories. It also provides Immune response consumables, such as interferon-gamma release assay for TB testing, and assays for post-transplant testing and viral load monitoring; oncology and sexual and reproductive health consumables, such as assays for prenatal testing and detection of sexually transmitted diseases and HPV; assays for analysis of genomic variants; and sample to insight instruments, including one-step molecular analysis of hard-to-diagnose syndromes, and integrated PCR testing. The company offers research PCR consumables, such as quantitative PCR, reverse transcription, and combinations kits for analysis of gene expression, genotyping and gene regulation, and running on QIAGEN instruments and technologies; human ID/forensics assay consumables, such as short tandem repeat assays for human ID, and assays for food contamination; PCR instruments, including digital PCR and qPCR solutions; and developed and configured enzymes and PCR solutions. It offers NGS gene panels, library prep kits and components, and whole genome amplification; QIAGEN consumables and instruments; bioinformatics solutions; and custom laboratory and genomic services. The company provides software-as-a-service. It serves molecular diagnostics, academia, pharmaceutical, and applied testing customers. The company was founded in 1984 and is headquartered in Venlo, the Netherlands.

Latest Life Sciences Tools & Services and Bio-Rad Laboratories, Inc., Qiagen N.V. Stock News

As of March 11, 2026, Bio-Rad Laboratories, Inc. had a $7.3 billion market capitalization, compared to the Life Sciences Tools & Services median of $1.1 million. Bio-Rad Laboratories, Inc.’s stock is NA in 2026, NA in the previous five trading days and up 8.93% in the past year.

Currently, Bio-Rad Laboratories, Inc.’s price-earnings ratio is 9.7. Bio-Rad Laboratories, Inc.’s trailing 12-month revenue is $2.6 billion with a 29.4% net profit margin. Year-over-year quarterly sales growth most recently was 3.9%. Analysts expect adjusted earnings to reach $10.227 per share for the current fiscal year. Bio-Rad Laboratories, Inc. does not currently pay a dividend.

Currently, Qiagen N.V.’s price-earnings ratio is 21.3. Qiagen N.V.’s trailing 12-month revenue is $2.1 billion with a 20.3% net profit margin. Year-over-year quarterly sales growth most recently was 6.1%. Analysts expect adjusted earnings to reach $2.511 per share for the current fiscal year. Qiagen N.V. currently has a 5.8% dividend yield.

How We Compare Bio-Rad Laboratories, Inc. and Qiagen N.V. Stock Grades

Stock evaluation requires access to huge amounts of data and the knowledge and time to sift through it all, make sense of financial ratios, read income statements and analyze recent stock movements. AAII created A+ Investor, a robust data suite that condenses data research in an actionable and customizable way suitable for investors of all knowledge levels, to help investors streamline and work through such data.

AAII’s proprietary stock grades come with A+ Investor. These offer intuitive A‐F grades for each of five key investing factors: value, growth, momentum, earnings estimate revisions and quality. Here, we’ll take a closer look at Bio-Rad Laboratories, Inc. and Qiagen N.V.’s stock grades to see how they measure up against one another.

Learn more about A+ Investor here!

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

Bio-Rad Laboratories, Inc. and Qiagen N.V. Stock Value Grades

Company	Ticker	Value
Bio-Rad Laboratories, Inc.	BIO	B
Qiagen N.V.	QGEN	C

Successful stock investing involves buying low and selling high, so stock valuation is an important consideration for stock selection.

Buying stocks that are going to go up typically means buying stocks that are undervalued in the first place, although momentum investors may argue that point.

AAII’s A+ Investor Value Grade derives from a stock’s value score. The Value Score is the percentile rank of the average of the percentile ranks of the price-to-sales ratio, price-earnings ratio, enterprise-value-to-EBITDA (EV/EBITDA) ratio, shareholder yield, price-to-book-value ratio and price-to-free-cash-flow ratio. The score is variable, meaning it can consider all six ratios or, should any of the six ratios not be valid, the remaining ratios that are valid. To be assigned a Value Score, stocks must have a valid (non-null) ratio and corresponding ranking for at least two of the six valuation ratios.

Stocks with a Value Score from 81 to 100 are considered deep value, those with a score between 61 and 80 are a good value and so on.

Bio-Rad Laboratories, Inc. has a Value Score of 63, which is Value. Qiagen N.V. has a Value Score of 48, which is Average.

The Value Stock Winner: Bio-Rad Laboratories, Inc.

As you can clearly see from the Value Grade breakdown above, Bio-Rad Laboratories, Inc. is considered to have better value than Qiagen N.V.. For investors who focus solely on a company’s valuation, Bio-Rad Laboratories, Inc. could be a good stock to add to their portfolio. However, it’s important for investors to analyze multiple factors based on a wide range of metrics before deciding whether to buy.

Bio-Rad Laboratories, Inc. and Qiagen N.V.’s Quality Grades

Company	Ticker	Quality
Bio-Rad Laboratories, Inc.	BIO	B
Qiagen N.V.	QGEN	A

Like the Value Grade, AAII’s A+ Investor Quality Grade comes from the percentile rank of key metrics. Specifically, the Quality Score is the percentile rank of the average of the percentile ranks of return on assets (ROA), return on invested capital (ROIC), gross profit relative to assets, buyback yield, change in total liabilities to assets, accruals, Z double prime bankruptcy risk (Z) score and the F-Score.

The score is variable, meaning it can consider all eight measures or, should any of the eight measures not be valid, the remaining measures that are valid. To be assigned a Quality Score, stocks must have a valid (non-null) measure and corresponding ranking for at least four of the eight quality measures.

The Quality Score is used to assess the underlying “quality” of a particular stock. A higher-quality stock possesses traits associated with upside potential and reduced downside risk. Backtesting of the Quality Grade shows that stocks with higher grades, on average, outperformed stocks with lower grades over the period of 1998 through 2019.

Stocks receive better grades (higher scores) for having higher scores for the quality subcomponents and worse grades (lower scores) for lower scores for the subcomponents.

Bio-Rad Laboratories, Inc. has a Quality Score of 63, which is Strong. Qiagen N.V. has a Quality Score of 87, which is Very Strong.

The Quality Grade Winner: Qiagen N.V.

As you can clearly see from the Quality Grade breakdown above, Qiagen N.V. has a better overall quality grade than Bio-Rad Laboratories, Inc.. For investors who are looking for companies with higher quality than others in the same industry, Qiagen N.V. could be a good stock to add to their portfolios. However, it’s important for investors to analyze multiple factors based on a wide range of metrics before deciding whether to buy.

Bio-Rad Laboratories, Inc. and Qiagen N.V.’s Estimate Revisions Grades

Company	Ticker	Earnings Estimate
Bio-Rad Laboratories, Inc.	BIO	C
Qiagen N.V.	QGEN	D

Earnings estimate revisions scores consider the magnitude of a company’s earnings surprise in its last two reported fiscal quarters. Often, positive surprises beget further positive surprises‐or at least continued sales growth (the exact opposite is generally true, too).

Estimate revisions offer an indication of what analysts are thinking about the short-term prospects of a firm. Estimate revisions are based on the statistical significance of a firm’s last two quarterly earnings surprises and the percentage change in its consensus estimate for the current fiscal year over the past month and past three months.

Bio-Rad Laboratories, Inc. has a Earnings Estimate Score of 50, which is Neutral. Qiagen N.V. has a Earnings Estimate Score of 40, which is Negative.

The Earnings Estimate Revisions Stock Winner: No Clear Winner

Neither Bio-Rad Laboratories, Inc. or Qiagen N.V. has an Earnings Estimate Revisions Grade that could be considered a “winner.” Investors considering these companies should do additional due diligence and research to see if either could be a good addition to their portfolios. It’s important to look at a wide range of financial metrics in order to determine if Bio-Rad Laboratories, Inc. or Qiagen N.V. is the better investment when it comes to estimate revisions.

Other Bio-Rad Laboratories, Inc. and Qiagen N.V. Grades

In addition to Quality, Value and Estimate Revisions, A+ Investor also provides grades for Growth and Momentum.

Momentum grades help uncover stocks experiencing anomalously high rates of return; research finds that stocks with high relative levels of momentum tend to outperform, whereas those with low levels of momentum tend to continue underperforming.

Growth investing builds on the idea that stocks of companies exhibiting strong, consistent and prolonged growth outperform those of slower-growth companies. AAII measures growth through consistency of annual sales growth, five-year sales growth rankings adjusted for extreme levels, and consistency of positive annual cash from operations.

These 2 key factors, when combined with the above, provide a holistic view into a particular stock. Further, by joining A+ Investor you can see whether Bio-Rad Laboratories, Inc. and Qiagen N.V. pass any of our 60+ stock screens that have outperformed the market since their creation.

So, Which Is the Better Investment, Bio-Rad Laboratories, Inc. or Qiagen N.V. Stock?

Overall, Bio-Rad Laboratories, Inc. stock has a Value Score of 63, Estimate Revisions Score of 50 and Quality Score of 63.

Qiagen N.V. stock has a Value Score of 48, Estimate Revisions Score of 40 and Quality Score of 87.

Comparing Bio-Rad Laboratories, Inc. and Qiagen N.V.’s grades, scores and metrics can act as a solid basis to determine whether they may be a good investment or not. You’ll also want to look at your portfolio’s asset allocation as well as your risk tolerance and financial goals to see if either of these stocks would make a good fit for you. AAII can help you figure out which investments align with your individual needs and preferences.

Investors are encouraged to do their own due diligence and research. In this way, individuals can effectively become managers of their own assets‐without having to rely on others for financial independence. You can count on AAII for timeless articles on financial planning and stock-picking, unbiased research and actionable analysis.

A+ Investor adds to our qualitative teaching with a powerful data suite to help you whittle down investment choices to find stocks, exchange-traded funds (ETFs) or mutual funds that meet your needs.

AAII Disclaimer

We make no representations or warranties that any investor will, or is likely to, achieve profits similar to those shown, because past, hypothetical or simulated performance is not necessarily indicative of future results. Before making an investment decision, you should consider your circumstances and whether the information on our content is applicable to your situation. This information was prepared in good faith, and we accept no liability for any errors or omissions. The full disclaimer can be read here.